Celularity up after FDA clears application for cancer drug's human trial

Celularity

29/11/2021 14:26

** Shares of biotech co  CELU.O  up ~2% at $6.89 premarket
    ** U.S. FDA clears co's application to start human trials
for its drug candidate, CYNK-101, in combination with standard
chemotherapy for treating patients with a type of gastric cancer
 urn:newsml:reuters.com:*:nGNX2PsMw6 
    ** CYNK-101 is an investigational cell therapy designed to
enhance a type of immune reaction to eliminate cancerous cells
with approved and novel antibody therapeutics
    ** Up to Friday's close, stock had fallen 38.64% YTD 

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))